- Home
- KRC vs CORT Comparison
KRC vs CORT Comparison
Compare KRC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | CORT |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1996 | 2001 |
Fundamental Metrics
Financial Performance| Metric | KRC | CORT |
|---|---|---|
| Price | $37.03 | $72.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $37.36 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.57% | N/A |
| EPS Growth | ★ 31.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,112,667,000.00 | $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | $2.13 | $26.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $27.36 | $28.66 |
| 52 Week High | $45.03 | $91.00 |
Technical Indicators
Market Signals| Indicator | KRC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 69.78 | 80.07 |
| Support Level | $32.94 | $68.20 |
| Resistance Level | $43.30 | $79.89 |
| Average True Range (ATR) | 0.92 | 2.57 |
| MACD | 0.13 | 0.87 |
| Stochastic Oscillator | 98.28 | 87.98 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.